Clal Insurance’s VanEck Pharmaceutical ETF PPH Stock Holding History

Clal Insurance’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-325,000	Closed	-$33.5M	–	226
2025 Q4	$33.5M	Hold	325,000	–	–	0.22%	76
2025 Q3	$29.4M	Hold	325,000	–	–	0.22%	73
2025 Q2	$28.6M	Buy	+325,000	New	+$28.2M	0.28%	64
2020 Q1	–	Sell	-14,285	Closed	-$222K	–	135
2019 Q4	$222K	Buy	+14,285	New	+$861K	0.24%	66
2016 Q3	–	Sell	-55,600	Closed	-$3.26M	–	110
2016 Q2	$3.26M	Hold	55,600	–	–	0.08%	73
2016 Q1	$3.2M	Sell	55,600 -8,200	-13%	-$485K	0.09%	66
2015 Q4	$4.18M	Sell	63,800 -32,400	-34%	-$2.09M	0.11%	61
2015 Q3	$6.06M	Buy	96,200 +36,900	+62%	+$2.59M	0.16%	58
2015 Q2	$4.2M	Buy	+59,300	New	+$4.27M	0.1%	69
2015 Q1	–	Sell	-212,940	Closed	-$13.7M	–	133
2014 Q4	$13.7M	Buy	+212,940	New	+$13.6M	0.33%	57

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

Clal Insurance's PPH Position: Q1 2026 in Review

Clal Insurance sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 325,000 shares — an estimated $33.5M sold.

Clal Insurance first reported a position in PPH in Q4 2014 and held it in 10 quarters. The position peaked at $33.5M in Q4 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

Clal Insurance reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
Clal Insurance sold 325,000 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $33.5M.
Clal Insurance first reported a position in VanEck Pharmaceutical ETF in Q4 2014 and held it in 10 quarters.
Clal Insurance's VanEck Pharmaceutical ETF position peaked at $33.5M in Q4 2025.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Clal Insurance's 13F filing for Q1 2026, filed 12 May 2026.